🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT06279676
Recruiting Observational

Improvement of Women's Health After Allogeneic Stem Cell Transplantation

NCT06279676 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2024-08-27
Last updated
2026-03-18

Condition(s) studied

GVHD, Chronic

Study summary

The aim of this prospective research project is to better understand vulvovaginal cGVHD to improve care of allografted women. The expected outcomes include better knowledge of the incidence and manifestations of vulvovaginal cGVHD, risk factors, response to treatments and impact on sexual health of allotransplanted female patients. The knowledge acquired will allow transplant clinicians to make more precise recommendations for gynecological management of future allografted women.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All women aged 18 and over who will receive a first allogeneic HSCT (bone marrow, peripheral blood stem cells from a related, unrelated (including cord blood) or haploidentical donor) at the CIUSSS-EMTL. Recruitment will begin when the project receives ethical approval. Recruitment period will be of 2 to 3 years. Exclusion Criteria: 1. Those who receive a second HSCT allograft. 2. Those who receive an autologous transplant. 3. Inability to give informed consent. 4. Unable to communicate in French or English. 5. Any other reason which, according to the investigators, makes it preferable for a patient not to participate.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CIUSSS de l'Est-de-l'Ile-de-Montréal / Hôpital Maisonneuve-Rosemont Montreal Quebec Recruiting

More Ciusss de L'Est de l'Île de Montréal trials in Canada

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06279676 on ClinicalTrials.gov ↗ ← All trials in Canada